News
& Events
News
& Events

News
& Events

Inversago Pharma to participate to BIO International Convention 2022 in San Diego, CA

MONTREAL (CANADA) – June 09, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announces that the company will be present at the upcoming BIO International Convention to be held in San Diego, CA June 13-16, 2022. – François Ravenelle, PhD, Chief Executive Officer […]

Read more

Inversago Pharma presents data on INV-202 in Diabetic Nephropathy at the ERA 2022 Congress

MONTREAL (CANADA) – May 19, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announces the presentation of preclinical data at the 59th Congress of the European Renal Association (ERA), the largest annual nephrology meeting in Europe, currently held in Paris, France. These data show […]

Read more

Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer

MONTREAL (CANADA) – May 17, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announces the appointment of Glenn S. Vraniak to the position of Chief Financial Officer (CFO), effective immediately. Mr. Vraniak’s career spans more than 20 years of financial and commercial experience […]

Read more

Inversago Pharma to participate to upcoming Bio€quity Europe 2022 to be held on May 16-18 in Milan, Italy and on May 23-24 virtually

MONTREAL (CANADA) – May 12, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announced that François Ravenelle, PhD, Chief Executive Officer and Glenn D. Crater, MD, FCCP, Chief Medical Officer, will take part to the Presenting Company Class of 2022 at Bio€quity Europe. […]

Read more